Business
Physiomics plc - Agreement
Physiomics plc - Agreement.
About this update from Valirx Plc
[{"type":"text","content":"\n \nFor release: 07:00 - 15th February 2007\n\n VALIRX PLC \n\n (\"ValiRx\" or the \"Company\") \n\n Physiomics plc Agreement \n\nValiRx (AIM: VAL), the cancer therapeutics company, today announces that it has\nsigned a new agreement with Physiomics plc (\"Physiomics\") (AIM: PYC), the\nEuropean systems biology simulation company, to use Physiomics' In Silico\nsimulations of cellular processes to reduce the development time and costs\nassociated in identifying new therapeutic compounds for the treatment of\ncancers.\n\nValiRx's subsidiary, Cronos Therapeutics Limited - developers of GeneICE - will\nbe the first ValiRx entity to use Physiomics' technology.\n\nIt is anticipated that by coupling GeneICE's ability to act on genes directly\nwith the predictive capacity of Physiomics' modeling expertise in biological\nsystems, it will be possible to optimise the development of possible therapies\nin terms of time and cost.\n\nDr Paul Harper, a Director of Physiomics, said:\n\n\"We look forward to deploying our simulation models to help predict and select\nthe optimal targets for ValiRx's break-through GeneICE technology.\"\n\nDr Satu Vainikka, CEO of ValiRx, added:\n\n\"Correct target selection at the outset is critical to reducing the time spent\n- and often lost - in the clinical trial process. We view our relationship with\nPhysiomics as important.\"\n\nThe primary concentration of the initial programme will be to investigate the\nprocess of Apoptosis (the natural process of programmed cell death and\nturnover) - a process that is frequently disrupted in Cancers.\n\nContact Details:\n\n ValiRx plc WH Ireland Physiomics plc GTH Communications \n \n Dr Satu Vainikka David Youngman Dr Paul Harper Toby Hall / Jade \n Mamarbachi \n \n +44 (0) 207 408 +44 (0) 161 832 +44 (0) 7747 +44 (0) 20 7153 8035 \n 5400 2174 842446 \n\n--- ENDS ---\n\nInformation on ValiRx plc\n\nValiRx is a biopharmaceutical development company that is building a portfolio\nof complementary cancer-related therapeutic and diagnostic technologies. It\ncurrently holds stakes in Cronos Therapeutics Limited and Morphogenesis Inc:\n\n * Cronos Therapeutics Limited holds licenses to two innovative and\n potentially market changing technologies, GeneICE and HyperGenomics. The\n Company has been informed by the European Patent Office that it is to\n receive the granting of...